期刊文献+

丙戊酸镁合并洛沙平治疗80例有精神病性症状躁狂发作的疗效观察

Treatment effect of magnesium valproate combination with loxapine for current episode manic with psychotic symptoms
下载PDF
导出
摘要 目的:比较单一大剂量洛沙平与丙戊酸镁合并小剂量洛沙平治疗有精神病性症状的躁狂发作的疗效和安全性。方法:将80例有精神病性症状的躁狂发作患者随机分成两组,分别接受为期6周的治疗。结果:在第6周末,单用洛沙平治疗组患者的临床总有效率为92.5%;丙戊酸镁合并小剂量洛沙平组的临床总有效率为97.5%;单用洛沙平组和丙戊酸镁合并洛沙平组的不良反应发生率分别为70.0%和40.0%,差异有显著性。结论:丙戊酸镁合并小剂量洛沙平治疗有精神病性症状的躁狂发作临床疗效优于单一大剂量洛沙平治疗且不良反应相对减少。 Objective: To compare the treatment effect and safety of single big dosage loxapine and magnesium valproate combining little dosage loxapine to treat current episode manic with psychotic symptoms. Methods:80 patients that had current episode manic with psychotic symptoms are accidentally divided into two groups and differently treated for 6 weeks. Results: On end of 6th, efficiency of the group of patients using loxapine is 92.5% , and clinical efficiency of the group of patients using magnesium valproate and little dosage loxapine is 97.5%. Side effect occurring rate of the group using loxapine is 70.0%. Side effect occurring rate of the group using magnesium valproate and loxapine is 40.0%. The difference is remarkable. Conclusions: Treatment effect of magnesium valproate and little dosage loxapine to treat current episode manic with psychotic symptoms is better than single big dosage loxapine. Side effect is relatively reduced.
出处 《中国民康医学》 2008年第17期1984-1985,共2页 Medical Journal of Chinese People’s Health
关键词 洛沙平 丙戊酸镁 有精神病性症状的躁狂发作 Loxapine Magnesium Valproate Current episode manic with psychotic symptoms
  • 相关文献

参考文献4

  • 1卫生部疾病控制司,中国疾病预防控制中心精神卫生中心,中华医学会精神病学分会,等.中国双相障碍防治指南(待出版),2003:40-41.
  • 2Kech PE, Perlis PH, Otto MW, et al. The expert consensus guideline: treatment of bipolar disorder 2004. Washington, USA: The McG raw - Hill Companies ,2004:20 - 27.
  • 3刘美兰.丙戊酸盐治疗情感性障碍[J].国外医学(精神病学分册),1990,17(1):14-18. 被引量:26
  • 4王立伟,武春艳.洛沙平——非典型的抗精神病药?[J].上海精神医学,2003,15(2):121-123. 被引量:21

二级参考文献8

  • 1[1]Kapur S, Zipursky RB, Jones C, et al. The D2 receptor occupancy profile of loxapine determined using PET. Neuropsychopharmacology.1996 Dec; 15(6): 562~566
  • 2[2]Roth BL, Craigo SC, Choudhary MS, et al. Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J Pharmacol Exp Ther 1994 Mar;268(3) :1403~1410
  • 3[3]Singh AN, Barlas C, Singh S, et al. A neurochemieal basis for the antipsychotie activity of loxapine: interactions with dopamine D1, D2 ,D4 and serotonin 5-HT2 receptor subtypes. J Psychiatry-Neurosci.1996 Jan; 21(1): 29~35
  • 4[4]Kapur S, Zipursky R, Remington G, et al. PET evidence that loxapine is an equipotent blocker of 5-HT2 and D2 receptors: implications for the therapeutics of schizophrenia. Am J Psychiatry. 1997 Nov;154(11): 1525~1529
  • 5[5]William M, Glazer MD. Dose loxapine have "Atypical" properties?clinical evidence. J C lin Psychiatry. 1999 ;60 (supple 10): 42~46
  • 6[6]Peter F, Buckley, MD. The role of typical and atypical antipsychotics medication in the management of agitation and aggression. J Clin Psychiatry. 1999 ;60(supple 10): 52~60
  • 7[7]Meltzer HY, Jayathilake K. Low-dose loxapine in the treatment of schizophrenia: is it more effective and more "atypical" than standard - dose loxapine? J Clin Psychiatry. 1999; 60 Suppl 10: 47~51
  • 8[9]Ereshefsky L. Pharmacologic and pharmacokinetic considerations in choosing an antipsychotic. J Clin Psychiatry. 1999; 60 Suppl 10: 20~30

共引文献45

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部